Systemic drug pricing reforms stall as TrumpRx prioritizes electoral gains over structural healthcare equity

Indigenous healthcare traditions universally treat medicine as a communal resource, not a commodity, challenging the Western pharmaceutical model’s profit-driven pricing. Systems like the Andean *ayni* (reciprocity-based medicine) or Māori rongoā (traditional healing) emphasize accessibility and collective well-being, contrasting with the TrumpRx framework’s individualistic, market-based approach. These models also highlight the role of ecological stewardship in drug discovery, where biodiversity conservation directly impacts affordable pharmacopeia. The erasure of such knowledge in U.S. policy reflects a broader colonial legacy in healthcare governance.

The U.S. drug pricing crisis traces back to the 1984 Hatch-Waxman Act, which extended patent monopolies and incentivized evergreening (incremental drug modifications to extend exclusivity). The Medicare Modernization Act of 2003 explicitly barred Medicare from negotiating drug prices, a policy rooted in pharmaceutical lobbying and the Reagan-era deregulatory ethos. Historical parallels abound in other sectors: the 19th-century patent medicine industry’s predatory practices mirror today’s EpiPen or insulin pricing schemes. The Trump administration’s MFN (Most Favored Nation) model, while novel in rhetoric, echoes Nixon’s 1970s wage-price controls—a short-lived attempt to curb corporate excess.

Canada’s Patented Medicine Prices Review Board (PMPRB) uses international benchmarking to cap drug prices, reducing costs by 20-40% compared to the U.S. without stifling R&D. In Brazil, the *Farmácia Popular* program subsidizes essential medicines, prioritizing public health over patent holder profits, with measurable reductions in mortality for chronic conditions. Japan’s *Yakkyoku* (pharmacy) system integrates price transparency and generic substitution, achieving near-universal access to affordable drugs. These models demonstrate that systemic price controls do not inherently suppress innovation but redistribute its benefits equitably.

Empirical studies show that Medicare drug price negotiation (as proposed in the Inflation Reduction Act) could save $100 billion over a decade by leveraging bulk purchasing power. Research from the *Journal of the American Medical Association* (2023) confirms that PBMs—middlemen in the drug supply chain—extract $200 billion annually in hidden rebates and fees, inflating prices for consumers. The scientific consensus supports compulsory licensing for life-saving drugs during crises, as evidenced by the WHO’s 2001 Doha Declaration on TRIPS flexibilities. Yet, U.S. policy remains mired in ideological resistance to evidence-based interventions.

Artistic expressions like *The Price of Everything* (2018 documentary) and *Dopesick* (Hulu series) critique the moral bankruptcy of pharmaceutical profiteering, framing it as a spiritual crisis of greed. Indigenous artists such as Jaune Quick-to-See Smith depict the commodification of medicine in works like *Trade (Gifts for Trading Land with White People)*, linking drug pricing to historical land dispossession. Spiritual traditions from Buddhism to Christianity explicitly condemn exploitation, with Pope Francis denouncing 'pharmaceutical colonialism' in 2020. These cultural critiques reveal drug pricing as a symptom of deeper societal values prioritizing profit over human dignity.

Scenario modeling by the *Lancet Commission on Essential Medicines* (2022) projects that global adoption of price controls and patent pooling could reduce drug costs by 60% by 2040, saving $1 trillion annually. A transition to open-source drug development—inspired by the COVID-19 mRNA vaccine collaborations—could democratize R&D, particularly for neglected diseases. The rise of AI-driven drug discovery may further disrupt monopolies, but only if paired with regulatory reforms preventing corporate capture. Without structural changes, the U.S. risks a bifurcated system where the wealthy access cutting-edge treatments while marginalized groups face rationed, unaffordable care.

Black and Indigenous communities in the U.S. face drug pricing disparities that exacerbate chronic illness mortality rates, with Black Americans 3x more likely to die from diabetes complications due to insulin inaccessibility. Disabled activists, such as those in the #Insulin4All movement, have documented how PBMs and insurers design formularies to exclude affordable generics, forcing patients into medical bankruptcy. Elderly populations in rural areas, often reliant on fixed incomes, are disproportionately affected by price hikes for essential medications like inhalers or blood pressure drugs. The framing of TrumpRx as a 'success' ignores these lived realities, treating marginalized voices as peripheral to the political narrative.